Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.
The duration of cell proadhesive effects induced by imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate (NAMI-A), a compound endowed with in vivo antimetastatic properties, was tested in vitro on the human epithelial tumor cell line KB. The intensity of proadhesive effects continues to increase up to 48 to 72 h after NAMI-A withdrawal and declines only after 96 h. The proadhesive effect on cells seeded on fibronectin is greater than on plastic, since it already reaches its maximum after 24 h. This effect suggests a role for integrin activation, which is further stressed by the inhibitory activity of the disintegrin molecule echistatin. The intensity and duration of NAMI-A's proadhesive effects are correlated to cell exposure time and to the rapid release of NAMI-A metabolites in the culture medium in the first 5 min after drug withdrawal. These metabolites are probably neutral species with ruthenium-bound bioligands to allow for the rapid exchange between cells and extracellular medium. These data suggest a long-lasting effect of NAMI-A in biological systems, even at very low concentrations, and stress the low and reversible effects on kidney, where it naturally concentrates. These data on proadhesive effects are, further, relevant for in vivo antimetastatic effects, as this adhesion is associated to cell motility and invasion, which in turn are related to tumor malignancy and metastasis.
Frausin
F
F
Department of Biomedical Sciences, University of Trieste, Italy.
Scarcia
V
V
Cocchietto
M
M
Furlani
A
A
Serli
B
B
Alessio
E
E
Sava
G
G
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins; D007624:KB Cells; D007668:Kidney / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008024:Ligands; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D012235:Rhodamines; D013054:Spectrophotometry, Atomic
D000970:Antineoplastic Agents; D005353:Fibronectins; D007093:Imidazoles; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D009942:Organometallic Compounds; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D012235:Rhodamines; C048589:imidazolium-bis(imidazole)tetrachlororuthenate(III); C057986:echistatin; C022027:lissamine rhodamine B